RxDoctor Payments Data

Allan Bernstein

Neurology · Sebastopol, CANPI 1992889067

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Biogen accounts for 91.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,769 and has fallen 96.5% since, to $63 in 2025.

$3,403in general payments, 2019–2025

Across 12 payments — averaging $283.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • Lilly USA, LLC$131
  • Eisai Inc.$49
  • Impel Pharmaceuticals Inc.$36
  • Eli Lilly$28
  • Amgen$26
  • plus $25 from 1 others
$2,575,542in research payments, 2019–2025

Across 55 payments — averaging $46,828 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.4M
  • Novartis$524K
  • Biogen$329K
  • Eisai Inc.$288K
  • Genentech, Inc.$81K

What the payments were for

  • Consulting fees$1,41342%
  • Speaking & faculty fees$1,69550%
  • Food & beverage$2959%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,403 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Other neurology in Sebastopol

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →